Myriad Genetics, Inc. provided earnings guidance for the fiscal year 2022. For the year, the company expects revenue to be in the range of $670 million to $700 million and GAAP LPS to be in the range of $0.90 to $0.70.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
23.9 USD | -0.54% |
|
+6.36% | +24.87% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.87% | 2.16B | |
-10.64% | 11.61B | |
-11.02% | 7.65B | |
+30.85% | 5.62B | |
-16.28% | 3.85B | |
+8.39% | 2.62B | |
-64.67% | 2.37B | |
-10.53% | 2.24B | |
-12.06% | 1.76B | |
-7.26% | 1.46B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022